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Abstract: Coronary heart disease (CHD) is a major health problem and a major cause of 
death in most countries. Evidence has been presented that gene polymorphisms (HindIII, 
PvuII and Ser447Ter) of lipoprotein lipase (LPL) are risk factors of coronary artery disease 
(CAD). Aim: Our objective of the present investigation was to determine whether 3 LPL 
polymorphisms (LPL-HindIII, LPL-PvuII and LPL-Ser447Ter) can be considered as 
independent risk factors for CAD in the Saudi population. Methods: We recruited   
120 CAD subjects, confirmed angiographically with identical ethnic backgrounds and   
65 control subjects. Polymerase chain reaction-restriction fragment length polymorphisms 
(RFLP) technique was used to detect the polymorphisms of the LPL gene.   
Results and conclusion: For the HindIII genotype, within the CAD group, the frequencies 
of the H
+H
+ were found in 50.8%, whereas 44.2% carried the H
−H
+ genotype, and 5% 
carried the H
−H
− genotype. Within the control group, the H
+H
+ genotype was found in 
44.6%, whereas 35.4% carried the H
−H
+ genotype, 20% carried the H
−H
− genotype. The 
odds ratio (OR) of HindIII genotype H
+H
+ vs. H
−H
− genotype at 95% Confidence Interval 
(CI) were 4.6 (1.57–13.2) and p < 0.005, hence showing no significant association with 
CAD. For the PvuII genotype, within the CAD group the frequencies of the P
+P
+ found in 
41.7% whereas 43.3.2% carried the P
−P
+ genotype, and 15% carried the P
−P
− genotype. 
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Within the control group the P
+P
+ was found in 38.5%, 43.0% carried the P
−P
+ genotype, 
and 18.5% carried the P
−P
− genotype. The OR of PvuII genotype P
+P
+ vs. P
−P
− genotypes 
(95% CI) is 1.33 and p = 0.52; hence, it was also insignificant to show association with the 
disease. For the Ser447Ter genotype, within the CAD group, the frequencies of the C/C 
found in 83.3%, whereas 16.7% carried the C/G genotype. Within the control group, the 
C/C was found in 87.7% and 12.3% carried the C/G genotype. We did not get any GG 
genotypes in control as well as patients for this gene. It can be concluded that C allele of 
gene masks the presence of G allele in the Saudi population. The OR of CG + GG vs. CC 
(95% CI) is 1.43 from 0.59 to 3.44 which is insignificant. Hence this gene also has no 
significant association with CAD in the Saudi population. 
Keywords: coronary artery disease; lipoprotein lipase; genotypes; restrictions fragment; 
Saudi populations and polymorphism 
 
1. Introduction 
In recent years, the relationship between the atherosclerotic cardiovascular disease, predominantly 
coronary artery disease (CAD) and many genetic variants in different populations are very well 
documented. CAD is one of the greatest causes of morbidity and mortality in all over the world being 
responsible for a high percentage of death annually in different countries [1,2]. It has been well known 
for decades that classical risk factors for CAD such as smoking tobacco or disorder in lipid metabolism 
increase its occurrence [3,4]. CAD shows strong familial aggregation, especially when it occurs at an 
early age and when many relatives are affected [5]. Lipid disorders have been associated as a   
well-known risk factors for CAD; however, only a small percentage of CAD patients have recognized 
monogenetic disease due to dysfunctional mutations in lipoproteins or lipoprotein-related genes (e.g., 
catabolic enzymes, receptors) [5]. Therefore, various risk factors remain unexplained [5,6] and this is 
believed to be due to the interaction of multi-factorial inheritance and environmental factors (e.g., diet, 
exercise, smoking) [5]. In this regard common variants of genes central to lipid metabolism that are 
associated with modest changes in protein function might be essential contributors to risk at a 
population level, maybe in association with other specific environmental and genetic factors [5,7]. The 
lipoprotein lipase (LPL) gene represents an excellent candidate to explain parts of the genetically 
determined risk of atherosclerosis [8]. Mature LPL is a 448 amino acid glycoprotein with 
chromosomal location 8p22 [9,10]. It is one of about 14 genetically mapped, lipid-related proteins 
known to be capable of contributing to the incidence of CAD [5]. Lipoprotein lipase, strategically 
anchored to vascular endothelium, plays a central role in lipid metabolism. Lipoprotein   
lipase-catalyzes hydrolysis of triglycerides of exogenous (chylomicron) and endogenous very low 
density lipoproteins (VLDL) origins to provide free fatty acids for oxidation in the heart and other 
tissues and for storage in adipose tissue [11]. Lipoprotein lipase is multifunctional, and is documented 
to have been involved as a ligand for low density lipoprotein (LDL) receptor-related protein and 
influences the hepatic secretion and uptake of VLDL and LDL cholesterol [12]. It is well known  
that rare LPL mutations cause marked dyslipidemias (e.g., familial LPL deficiency with Int. J. Mol. Sci. 2012, 13  7561 
 
chylomicronemia [13], at least some of which are known to be involved in the development of 
premature atherosclerosis [13]. However, we were interested in exploring the relationship between 
LPL polymorphisms and the risk for CAD by detecting the frequencies of LPL HindIII, PvuII and 
Ser447Ter genotypes in the Saudi population. Several polymorphic variants of the LPL gene have 
been identified in recent years and evaluated for their effects on plasma lipids and atherosclerosis risk 
from different populations [14–18]. Those defined by the HindIII, PvuII and Ser447Ter restrictions 
fragment length polymorphism sites, located on introns 8, 6 and 9 respectively, of the LPL gene, are 
common and may be associated with subtle alterations in plasma lipids. Various studies on HindIII, 
PvuII and Ser447Ter polymorphisms and their association with diseases related to CAD have been 
previously reported. The HindIII, PvuII and Ser447Ter polymorphisms have been variably reported to 
associate with CAD [14–20]. However, the results are inconsistent [17,18,21]. Therefore, given the 
importance of LPL as a candidate gene for CAD risk, we have evaluated independent Saudi and well 
defined, ethnically relatively homogenous and angiographically controlled Saudi population to 
determine whether the HindIII, PvuII and Ser447Ter polymorphisms are associated with the risk of the 
development of CAD. 
2. Results and Discussion 
Characteristics of the 185 study subjects (120 CAD) patients and (65 control subjects) are presented 
in Table 1. Plasma level of Fasting blood sugar (FBS), triglycerides (TG), total cholesterol (TC) and 
low density lipoprotein-cholesterol (LDL-c) tended to be higher and HDL-c lower in CAD patients 
than in controls at admission. Table 1 shows the plasma level of fasting blood glucose, triglycerides, 
total cholesterol and low density lipoprotein cholesterol were significantly higher in CAD group   
(p < 0.001) as compared to normal control group. 
Table 1. Characteristic of Controls and coronary artery disease (CAD) Patients. 
Characteristic Controls  n = 65  CAD group n = 120  p-value 
Age, year 
Mean ± SD 
Range 
 
49.02 ± 19.73 
(17.0–78.0) 
 
61.94 ± 10.78 
(31.0–89.0) 
<0.001 
Gender 
Male, % 
Female, % 
 
29(44.6) 
36(55.4) 
 
58(48.33) 
62(51.67) 
<0.001 
FBS, mmol/L 
Mean ± SD 
Range 
 
4.54 ± 0.58 
(3.26–5.62) 
 
7.79 ± 3.68 
(3.3–20.6) 
<0.001 
TG, mmol/L 
Mean ± SD 
Range 
 
1.06 ± 0.28 
(0.53–1.72) 
 
1.56 ± 0.70 
(0.57–3.77) 
<0.001 
TC, mmol/L 
Mean ± SD 
Range 
 
3.80 ± 0.48 
(3.01–5.11) 
 
4.24 ± 1.09 
(0.77–7.5) 
<0.001 Int. J. Mol. Sci. 2012, 13  7562 
 
Table 1. Cont. 
Characteristic Controls  n = 65  CAD group n = 120  p-value 
HDL-c, mmol/L 
Mean ± SD 
Range 
 
1.26 ± 0.39 
(0.76–2.11) 
 
1.11 ± 0.88 
(0.53–5.1) 
N.S 
LDL-c, mmol/L 
Mean ± SD 
Range 
 
1.65 ± 0.33 
(1.0–2.5) 
 
2.53 ± 0.91 
(1.01–4.89) 
<0.001 
Data are represented as mean ± SDs for all quantitative traits. Student’s t-test and χ
2 test were used 
to compare the values of controls and CAD patients. 
Many studies have focused on the relationship between LPL gene polymorphism and the incidence 
of cardiovascular disease in various populations [14,16,19,21,22]. Some studies investigated the 
influence of LPL gene activity on levels of plasma TG, TC, HDL-c and apolipoproteins, but the results 
are inconsistent [17,22–26]. Clee et al. (2000) [23] demonstrated that decreased plasma LPL activity is 
associated with high TGs and low HDL phenotypes in patient samples and Ser447Ter mutation is 
associated with higher plasma LPL activity. Given the importance of LPL as a candidate gene for 
CAD risk, we evaluated a reasonably small, independent, well-defined, angiographically controlled 
Saudi population to determine whether the LPL-HindIII, LPL-PvuII and LPL-Ser447Ter polymorphisms 
were associated with defined CAD in individuals of Saudi origin.  
Diabetes mellitus, dyslipidemia, hypertension and smoking, were selected as risk factors. The 
frequencies of major CAD risk factors are summarized in Table 2. Diabetes mellitus, dyslipidemia, 
hypertension, and smoking were more frequent in the CAD patient group than in controls. Diabetes 
mellitus, dyslipidemia and hypertension were found to be risk factors for CAD (Odds 17.8, 6.4, and 
18.02 respectively, p < 0.0001) whereas no such association was observed for smoking (odds 1.49  
p = 0.31). Coronary artery disease (CAD) is a multifactorial disorder that is thought to result from an 
interaction between genetic back ground and environmental factors such as diet, smoking, and physical 
activity. It is usually associated with conventional risk factors, including hypertension, diabetes 
mellitus, and hypercholesterolemia [27]. In general, individuals with hypertension, diabetes mellitus, 
and hypercholesterolemia and those with none of these factors are considered at high and low risk, 
respectively, for development of CAD. Age, smoking, hypertension, and diabetes have been established 
as independent risk factors for ischemic CVD [28]. Hypertension and dyslipidemia were found to 
influence CAD [29]. Genetic factors were statistically independent of age, smoking, or hyperuricemia, 
as well as hypertension, diabetes mellitus, and hypercholesterolemia. The results indicated that 
smoking is an important environmental factor for CAD in low-risk men, consistent with the notion that 
the cessation of smoking is important in the prevention of CAD in these individuals [28]. 
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Table 2. Risk Factors for Coronary Artery Disease in Patients and Control Subjects. 
Paramerter CAD  n = 120  Control n = 65  OR  95% CI  p * 
Diabetes mellitus 
Diabetic 
Non diabetic 
 
82(68%) 
38(32%) 
 
7(11%) 
58(89%) 
 
 
17.8 
 
 
7.46–42.8 
 
 
0.0001 
Dyslipidemia 
 Positive 
 Negative 
 
65(54%) 
55(46%) 
 
12(18%) 
65(82%) 
 
 
6.4 
 
 
3.14–13.05 
 
 
0.0001 
Hypertension 
 Hypertensive 
 Normotensive 
 
86(72%) 
34(28%) 
 
8(12%) 
57(88%) 
 
 
18.02 
 
 
7.78–41.73 
 
 
0.0001 
Smoking 
 Smoker 
 Nonsmoker 
 
28(23%) 
92(77%) 
 
11(17%) 
54(83%) 
 
 
1.49 
 
 
0.69–3.24 
 
 
0.31 
* p < 0.05; CI = confidence interval. 
The polymorphic allele displaying the restriction site were designated with a plus sign (+) and the 
allele without the site with a minus sign (−). The identified genotypes were named according to the 
presence or absence of the enzyme restriction sites, HindIII and PvuII (+/+), (+/−), and (−/−) are 
homozygote’s for the presence of the site, heterozygote’s for the presence and absence of the site, and 
homozygote’s for the absence of the site, respectively. 
The HindIII genotypes were determined by PCR and digestion using HindIII restriction enzyme. 
When present, the HindIII resulted in fragments of 600 bp after digestion (Figure 1). The LPL-HindIII 
genotypes were determined according to Anderson et al. 1999 [1]. 
Figure 1. 2.5% Agarose gel electrophoresis cutting with HindIII. Lane 1, 100 bp DNA 
molecular weight marker. Lanes 2–8, lipoprotein lipase (LPL) PCR product digested with 
HindIII. Homozygosity for presence (lanes 2–4), heterozygosity (lanes 5, 6), and 
homozygosity for absence (lanes 7, 8) of restriction site are shown. 
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The PvuII genotypes were determined by PCR and digestion using the PvuII restriction enzyme. 
When present, PvuII produces fragments of 330 and 110 bp (Figure 2). The LPL-PvuII genotypes were 
determined according to Anderson et al. 1999 [1]. 
Figure 2. 2.5% Agarose gel electrophoresis cutting with PvuII. Lane 1, 100 bp DNA 
molecular weight marker. Lanes 2–8, LPL PCR product digested with PvuII. 
Homozygosity for presence (lanes 2–4), heterozygosity (lanes 5, 6), and homozygosity for 
absence (lane 7, 8) of restriction site are shown. 
 
The Ser447-Ter genotypes were determined by PCR and digestion using the MnlI restriction 
enzyme. The identified genotypes were named to the presence or absence of the enzyme restriction 
sites, so Ser447-Ter GG, CG, and CC are homozygote for the presence of the site, heterozygote for the 
presence and absence of the site, and homozygote for the absence of the site, respectively. The PCR 
product of 448 bp contains 2 MnlI restriction sites, one of which is a polymorphic site indicating the 
Ser447-Ter mutation. Digestion of the PCR product with MnlI resulted in three fragments of 290, 250, 
and 200 bp (Figure 3). LPL-Ser447-Ter mutations were determined according to Sawano et al. 2001 [18]. 
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Figure 3. 2.5% Agarose gel electrophoresis cutting with MnlI. Lane 1, 100 bp DNA 
molecular weight marker. Lanes 2–8, LPL PCR product digested with MnlI. Homozygosity 
for presence lanes 2–5 and 8, heterozygosity lanes 6, 7 of restriction site are shown. 
 
Genotype Distribution and Allele Frequency of the LPL-HindIII, LPL-PvuII and LPL-Ser447Ter 
Genotype frequencies did not deviate from Hardy-Weinberg expectations in both controls and CAD 
group. The genotype distribution and the allele frequency for LPL gene polymorphisms are 
summarized in Table 2. H
+ and H
− alleles did not differ significantly between CAD group and 
controls. For the HindIII genotype, within the CAD group (n = 120), the frequencies of the H
+H
+ 
found in 61 individuals (50.8%), whereas 52 (44.3%) carried the H
−/H
+ genotype, and 6 (5%) carried 
the H
−/H
− genotype. Within the control group (n = 65), the H
+/H
+ genotype was found in 29 (44.6%), 
whereas 23 (35.4%) carried the H
−/H
+  genotype, and 13.0 (20%) carried the H
−H
−  genotype. the 
distribution of HindIII demonstrated that CAD patients had lower H
−H
− frequency compared to the 
control group and higher H
+H
−, H
+H
+ frequencies compared to the control group Table 3. Odds Ratios 
were 4.5 and 4.6 respectively when compared with (H
−H
−) genotype. Individuals with homozygous 
(H
+H
+) or (H
+H
−) genotype were at much higher risk of developing CAD compared to the (H
−H
−) 
genotype (p < 0.005), Table 4. For the PvuII genotype, within the CAD group (n = 120), the frequencies 
of the P
+P
+ found in 50 (41.7%), whereas 52 (43.2%) carried the P
−P
+ genotype, and 18 (15%) carried 
the P
−P
− genotype. Within the control group (n = 65), the P
+P
+ was found in 25 (38.5%), 28 (43.0%) 
carried the P
−P
+ genotype, and 12.0 (18.5%) carried the P
−P
− genotype. The distribution of PvuII 
polymorphism demonstrated that CAD patients had higher P
+P
−, P
−P
−, P
+P
+ frequencies compared 
with controls, Table 3. The odds ratios of PvuII genotype P
−P
− vs. P
−P
+ and P
+P
+ genotypes (95% CI) is 
1.26 (90.53–2.99) and 1.33 (0.56–3.20) respectively, hence showing no significant association with 
CAD disease Table 5. In previous studies, the prevalence rate of the LPL-HindIII (H
+H
+) genotype 
was implicated as the most common genotype associated with CAD. Shimo-Nakanishi et al. (2001) [17] Int. J. Mol. Sci. 2012, 13  7566 
 
demonstrated that HindIII polymorphism is associated with increased risk of atherothrombotic 
infarction. Likewise, Chamberlain et al. (1989) [30] indicated that there were differences in frequencies 
of both HindIII and PvuII alleles between Whites and Japanese populations, the statistical analysis for 
the LPL-HindIII genotypes indicates significant differences in the distribution of these genotypes 
between the control groups and the CAD groups, which in agreement with previous reported study [20]. 
Several studies have investigated the possibility that the LPL-HindIII and the LPL-PvuII polymorphisms 
are associated with the severity of CAD in various populations [1,14,16,19,20,31–36]. However, 
limited data are available concerning the Saudi population [21], which has not adequately defined the 
association between LPL polymorphism and CAD. While a large number of studies have found the 
LPL-HindIII (H
+H
+) genotype to be associated with CAD, the finding from the association studies 
with LPL-PvuII polymorphisms have been inconsistent [14,15,19,33,35]. For example, Thorne et al.  
(1990) [15] reported an increase in the LPL-HindIII (H
+H
+) genotypic frequencies in patients with 
coronary atherosclerosis in Japanese population whereas Peacok et al. (1992) [33] observed no 
differences in either LPL-HindIII or LPL-PvuII allelic frequencies in young survivors of myocardial 
infarction in Spanish population. Ukkola et al. (1995) [35] found reductions in various measures of 
ischemic heart disease in non-insulin-dependent diabetics who were LPL-PvuII (P
+P
+), but noted 
increases in those who were LPL-HindIII (H
−H
−) in Canadian adult population. In contrast,   
Gerdes et al. (1995) [34] found the LPL- HindIII (H
+H
+) genotype to be positively associated with a 
family history of premature ischemic heart disease in a group of Danish men. Similarly,   
Mattu et al. (1994) [32] found an association between the LPL-HindIII H
+H
+ genotype and CAD, but 
not between the LPL-PvuII (P
+P
+) genotype and CAD in native Brazilian population. On the other 
hand, Wang et al. (1996) [14] reported an association between the extent, but not occurrence of CAD 
and the LPL-PvuII (P
+P
+) genotype. However, in the same study, Wang et al. (1996) [14] found no 
association between the LPL-HindIII genotype and CAD. Interestingly, Gambino et al. (1999) [31] 
found a striking association between the LPL-HindIII (H
+H
+) genotype and multi-vessel disease in an 
Italian group of young survivors of myocardial infarction. Also it has been reported that   
Anderson et al. (1999) [1] found a moderate association between the LPL-HindIII (H
+H
+) genotype 
and CAD, whereas the LPL-PvuII (P
−P
−) genotype was modestly associated with CAD. In summary, 
the relevance of these genotypes may vary among different populations. 
Table 3. Genotype distributions and allele frequency of the HindIII, PvuII and Ser447Ter. 
Genotype, n (%) Allele frequency 
HindIII 
Control (n = 65) 
Patient (n = 120) 
H
−H
− 
13.0(20%) 
6.0(5%) 
H
−H
+ 
23.0(35.4%) 
53.0(44.2%) 
H
+H
+ 
29.0(44.6%) 
61.0(50.8%) 
H
+ allele 
0.62 
0.73 
H
− allele 
0.38 
0.27 
PvuII 
Control (n = 65) 
Patient (n = 120) 
P
−P
− 
12.0(18.5%) 
18.0(15%) 
P
−P
+ 
28.0(43.0%) 
52.0(43.3%) 
P
+P
+ 
25.0(38.5%) 
50.0(41.7%) 
P
+ allele 
0.60 
0.63 
P
− allele 
0.40 
0.37 
Ser447Ter 
Control (n = 65) 
Patient (n = 120) 
CC 
57.0(87.7%) 
100(83.3%) 
CG 
8.0(12.3%) 
20.0(16.7%) 
 
G allele 
0.061 
0.083 
C allele 
0.93 
0.917 
χ
 test was used to compare the allele frequencies between control and CAD patients. Int. J. Mol. Sci. 2012, 13  7567 
 
Table 4. Plasma concentrations of triglycerides (TG), total cholesterol (TC), high density 
lipoprotein-cholesterol (HDL-c) and low density lipoprotein-cholesterol (LDL-c) in 
various genotypes of the HindIII, PvuII and Ser447Ter in CAD patient group. 
Genotype  TG (mmol/L)  TC (mmol/L)  HDL-c (mmol/L)  LDL-c (mmol/L) 
HindIII 
H
−H
− 
H
−H
+ 
H
+H
+ 
p-value 
 
1.47 ± 0.28 
1.59 ± 0.71 
1.53 ± 0.72 
0.722 
 
4.48 ± 1.51 
4.26 ± 0.95 
4.19 ± 1.18 
0.664 
 
0.96 ± 0.18 
1.01 ± 0.27 
1.23 ± 1.22 
0.434 
 
3.02 ± 1.23 
2.49 ± 0.82 
2.51 ± 0.96 
0.453 
PvuII 
P
−P
− 
P
−P
+ 
P
+P
+ 
p-value 
 
1.37 ± 0.41 
1.53 ± 0.70 
1.64 ± 0.75 
0.108 
 
4.57 ± 1.07 
4.09 ± 1.05 
4.28 ± 1.13 
0.848 
 
1.14 ± 0.37 
1.16 ± 1.23 
1.05 ± 0.47 
0.453 
 
2.85 ± 0.94 
2.51 ± 0.83 
2.46 ± 0.98 
0.375 
Ser447Ter 
CC 
GC 
p-value 
 
1.57 ± 0.70 
1.48 ± 0.66 
0.171 
 
4.28 ± 1.10 
4.06 ± 1.03 
0.721 
 
1.13 ± 0.96 
1.03 ± 0.23 
0.708 
 
2.55 ± 0.92 
2.45 ± 0.93 
0.482 
Table 5. Odds Ratios for CAD Associated With Carriage of HindIII-,  PvuII- and   
Ser-447/Ter Carrying Genotypes. 
 Odds  Ratio  95%CI  p 
HindIII genotypes 
HindIII (H
+H
−) vs. HindIII (H
−H
−) 
HindIII (H
+H
+) vs. HindIII (H
−H
−) 
HindIII (H
+H
+) and HindIII (H
+H
−) vs. HindIII (H
−H
−) 
 
4.5 
4.6 
4.8 
 
(1.69–14.76) 
(1.57–13.20) 
(1.71–13.19) 
 
0.004 * 
0.005 * 
0.003 * 
PvuII genotypes 
PvuII (P
+P
−) vs. PvuII (P
−P
−) 
PvuII (P
+P
+) vs. PvuII (P
−P
−) 
PvuII (P
+P
+) and PvuII (P
+P
−) vs. PvuII (P
−P
−) 
 
1.26 
1.33 
1.42 
 
(0.53–2.99) 
(0.56–3.20) 
(0.64–3.16) 
 
0.60 
0.52 
0.39 
Ser-447/Ter genotypes 
Ser-447/Ter CG+GG vs. Ser-447/Ter CC 
 
1.43 
 
(0.59–3.44) 
 
0.43 
* p < 0.05; CI = confidence interval. 
For the Ser447Ter genotype, within the CAD group (n = 120), the frequencies of the CC found in 
100 (83.3%), whereas 20 (16.7%) carried the CG genotype. Within the control group (n = 65), the CC 
was found in 57 (87.7%) and 8 (12.3%) carried the CG genotype. We did not get any GG genotypes in 
the control or any patients for this gene. The homozygote of G allele was incorporated with the 
heterozygote due to the low frequency of GG, higher frequencies of CC and CG genotypes in the CAD 
group Table 3. OR of CC vs. CG+GG (95% CI) is 1.43 from 0.59 to 3.44, which is insignificant,  
Table 4. Interestingly, no GG genotype was observed in the CAD and control groups in the distribution 
of Ser447Ter polymorphism in the present study. However, we found for the first time in Saudi 
populations new genotype frequencies of Ser447-Ter mutations of the LPL gene between the CAD 
patients and the healthy controls. In previous reported studies, the frequency of the Ser447-Ter genotype Int. J. Mol. Sci. 2012, 13  7568 
 
of GG and CG was significantly lower in a group of Japanese CAD patients than in the control [37], 
representing a significantly low risk of CAD. Also Shimo-Nakanishi et al. (2001) [17] found that 
Ser447 Stop mutations of the LPL gene are a novel genetic marker for low risk of atherothrombotic 
cerebral infarction. Kozaki et al. (1993) [37] originally found an approximately 2-fold increase in the 
enzymatic activity of LPL resulting from the Ser447-Ter mutations at the carboxy terminal of LPL 
transfected and expressed in vitro, conflicting results that demonstrated that Ser447-Ter mutations 
might have either no or an inverse effect on LPL function may have been caused by different methodology. 
Haplotype frequencies for the HindIII, PvuII and Ser447Ter alleles were estimated for controls and 
patients (Table 6). A score for each haplotype (Hap-score) was calculated and the P-value was 
obtained for the significance of each Hap-score. The haplotypes −/−/C, +/−/C, −/−/G, −/+/C, −/+/G, 
+/−/G, +/+/C and +/+/G are the most common in the CAD patients group. There were differences 
between the CAD group and control group with regards to the haplotype distribution. Comparison of 
the common haplotype frequencies between the CAD patients group and control group revealed a 
significant increase in the frequency of the most common haplotype in those with CAD. This also 
suggests an increase in the frequency of less common haplotypes among some cases. Haplotypes 
−/−/G and +/+/C were associated with a significantly increased risk factor of CAD (p = 0.06, 0.04 
respectively). Table 6 Shows that combined genotypes may play an important role in the process of 
atherogenesis. It has been proposed that the H
−allele is a marker either for a mutation that alters an 
amino acid within LPL, causing enzyme activity or lipid binding to be more efficient, or possibly for a 
sequence change within the promoter, causing higher levels of LPL expression [20]. The frequencies 
of H
−/C and P
−/C were significantly higher in CI patients than in controls, and the H
−/P
−/C combined 
genotype was the most common genotype of HindIII/ PvuII/ Ser447Ter combined genotypes in the 
cerebral infarction group. P
−allele is more frequent and G allele is less frequent in cerebral infarction 
(CI) patients than in controls. The data also provide strong evidence of an association between 
polymorphisms in the LPL gene with lipid levels. Moreover, H
−/C and P
−/C mutations, especially 
H
−/P
−/C mutation of the LPL gene, are relevant to CI. PvuII polymorphism is a risk factor for CI while 
Ser447Ter mutation is a protective factor, indicating that the LPL polymorphism remains a useful 
genetic marker for predicting CI risk in the Chinese [19]. Goodarzi et al. 2003 [38] showed no 
differences between cases and controls, in comparison of genotype frequencies except for a modestly 
significant difference for the 8393 (HindIII) variant (p = 0.05). However, comparison of the common 
haplotype frequencies between the Mexican-Americans with and without coronary artery disease 
revealed a significant decrease in the frequency of the most common haplotype in those with disease. 
Goodarzi et al. 2003 found that six markers in the 3' end of LPL allowed us to distinguish the most 
common haplotypes occurring in two major U.S. ethnic groups, Hispanic and non-Hispanic 
Caucasians. The allele and haplotype frequencies were different between the Mexican-Americans and 
non-Hispanic Caucasians. Furthermore, within the Mexican-Americans, there were positive and 
negative associations of particular haplotypes with coronary artery disease, suggesting a role of this 
gene in contributing to CAD in this population. In comparing two different ethnic groups,   
Goodarzi et al. 2003 [38] found several differences in the allele and haplotype frequencies observed in 
the 3′LPL markers. Such differences may affect the results of association studies conducted in   
different populations. 
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Table 6. Haplotypes analysis of lipoprotein lipase polymorphism in CAD patients and controls. 
HindIII  PvuII  Ser447Ter  Number in CAD patient/120  Number in control/65  p 
−  −  C  43 (35.83%)  22 (33.85%)  0.787 
+  −  C  70 (58.33%)  33 (50.76%)  0.323 
−  − G  12  (10.0%)  1(1.54%)  0.06 
−  +  C  45 (37.5%)  27 (41.54%)  0.59 
−  +  G  9 (7.5%)  5 (7.69%)  0.96 
+  −  G  10 (8.33%)  3 (4.61%)  0.35 
+  +  C  94 (78.33%)  42 (64.62%)  0.04 
+ +  G  14(11.67%)  6  (9.23%)  0.61 
(−) wild-type; (+) mutant in HindIII and PvuII. (C) wild-type; (G) mutant in Ser-447/Ter.   
(−/−/C reference haplotype). 
3. Experimental Section 
3.1. Patient and Control Population  
Study patients and control subjects consisted of 120 patients (58 male and 62 female, aged   
36–80 years) who were admitted to Department of Cardiology, King Khalid University Hospital, 
Riyadh, Saudi Arabia, and 65 healthy subjects (29 male and 36 female, aged 32–80) who had no 
history of CAD as control. Included subjects were of unrestricted age and gender who gave written 
informed consent to draw blood at the time of angiography or at the time of screening for research 
deoxyribonucleic acid (DNA) extraction to be used in studies approved by the hospital’s institutional 
review board and was conducted in accordance with the guidelines set by the ethics committee of 
College of Medicine and Research Centre (CMRC) of King Saud University, Riyadh, Saudi Arabia. 
All subjects enrolled in this study were Saudi residents with similar dietary pattern. Key demographic 
data of subjects were recorded including age and gender lipid profile. Assessment of CAD was made 
by review of angiograms by the patient’s cardiologist.  
3.2. Ethical Approval  
This study was conducted after review and approval of the Institutional Review Board of the Ethics 
Committee at KKUH (King Khalid University Hospital), and all subjects gave written informed 
consent prior to participation. 
3.3. Plasma Lipid Measurements 
Blood samples for the glucose and lipid measurements were withdrawn from the patients and the 
control subjects after an overnight fast. The plasma glucose concentration was measured by the 
glucose oxidase method using a Biotrol Kit on a Bayer opera analyzer. Serum total cholesterol was 
measured using the Biotrol commercial Kit, HDL cholesterol was determined with a commercial 
Randox Kit, LDL cholesterol was calculated by the formula of Friedwald, and triglyceride 
determination was made by the method of Lipase/Glycerol Kinase UV endpoint on the opera analyzer. 
   Int. J. Mol. Sci. 2012, 13  7570 
 
3.4. DNA Extraction 
Genomic DNA was extracted from peripheral blood specimens, which were in tubes containing 
EDTA, which performed as an anticoagulant, using QIAamp DNA isolation Kit from   
QIAGEN (Germany). 
3.5. Genotyping 
Genotyping was performed by polymerase chain reaction (PCR). The primer sets were selected on 
the basis of previously published information (18): HindIII, forward primer (H1), 5'-TGA AGC TCA 
AAT GGA AGA GT-3', reverse primer (H2): 5'-TAC AAG CAA ATG ACT AAA-3'; PvuII, forward 
primer (P1): 5'-ATG GCA CCC ATG TGT AAG GTG-3'; reverse primer (P2): 5'-GTG AAC TTC 
TGA TAA CAA TCT C-3'; Ser447Ter, forward primer: 5'-TAC ACT AGC AAT GTC TAG GTG  
A-3', reverse primer: 5'-TCA GCT TTA GCC CAG AAT GC-3'. Genomic DNA template 3 µL (150 
ng) was added to PCR reaction mixture composed of 12.5 µL 2× Promega master mix, 2 µL each 
primer and distilled water to a final volume 25 µL. The PCR condition were as follows: initial 
denaturation at 94 °C for 2 min were followed by 40 cycles of denaturation at 94 °C for 15 s, annealing 
at 50 °C for 30 s, and extension at 72 °C for 1 min, with final extension at 72 °C for 2 min in  
My Cycler (Bio-Rad). 
3.6. LPL Gene Polymorphism Analysis 
Digestion of PCR products was performed by addition of 1 µL of the respective restriction enzyme 
(HindIII: Promega, Madison WI, USA; PvuII: Promega, Madison WI, USA, MnlI: England Biolabs, 
Inc.) to 10 µL of PCR products in 2 µL 10× buffer solution (final reaction volume = 20 µL), and 
centrifuged for 2 min at the speed of 5000 rounds/min, and aqueous bathed at 37 °C for 4 h. The 
resulting fragments were resolved by electrophoresis (80 V, 60 min) on 2.5% agrose gel, and 
visualized on UV light. 
The  HindIII site (intron 8) produces a 600-bp fragment after digestion (Figure 1). The PvuII 
restriction site (intron 6) yields 330-bp and 110-bp fragments (Figure 2). Genotypes were scored by an 
experienced reader blinded to clinical and angiographic results. Our convention was to refer to the 
polymorphic allele displaying the restriction site as (+) and the allele without the site as (−). For both 
PvuII and HindIII, the (−) allele was less common R [1]. 
The PCR product of 488 bp contains 2 MnlI restriction sites, of which one is a polymorphic site 
indicating the Ser447Ter mutation. Digestion of the PCR product with MnlI resulted in 3 fragments of 
290, 250, and 200 bp. [17,18]. The identified genotypes were named according to the presence or 
absence of the enzyme restriction sites, so Ser447Ter GG, CG, and CC are homozygote for the 
presence of the site, heterozygote for the presence and absence of the site, and homozygote for the 
absence of the site, respectively (Figure 3). 
3.7. Statistical Analysis 
Measurement data were summarized by mean ± standard deviation (S.D.), and compared with   
two-sample  t-test. Enumeration count data were summarized as number (%) and compared with  Int. J. Mol. Sci. 2012, 13  7571 
 
chi-square test (χ
2 test). To analysis was used to evaluate the allelic and genotypic frequencies that 
were calculated from the observed genotypic counts and to assess the Hardy-Weinberg equilibrium 
expectations. The same methodology was applied to comparisons between allelic and genotypic 
frequencies. Associations were determined as odds ratios (ORs) and 95% confidence intervals (CIs). 
(The odds of carrying a specific allele are defined as the frequency of subjects in whom it occurs 
divided by the frequency of subjects in whom it does not occur. The odds ratio for the LPL genotype 
distribution χ
2 analysis was performed. A CAD is the odds of allelic carriage in the diseased [CAD] 
group divided by the odds in the undiseased [control] group.) Univariate logistic regression was used 
to determine adjusted ORs for the genetic markers, conditioned on the major CAD risk factors.   
(p value < 0.05 was considered statistically significant). Statistical analyses were performed with the 
Statistical Package for Social Sciences for Windows, version 11.5 (SPSS, Inc, Chicago, IL, USA). 
4. Conclusions 
We found association of HindIII polymorphism with CAD, and no association of PvuII and 
Ser447Ter polymorphisms with CAD. There were no significant differences in the serum levels of TC, 
TG, HDL-c and LDL-c with H
−H
−, H
−H
+, H
+H
+ genotypes (Table 4). Also P
−P
−, P
−P
+, P
+P
+ and CC 
and CG+GG alleles did not correlate significantly with plasma levels of TC, TG, HDL-c and HDL-c 
hence showing no association between these polymorphisms and CAD. Furthermore, our study did not 
show any protective role of H
+ P
+ or G allele (Table 3) against the onset of the disease. Hence, CAD 
may be a complex disorder of combination of both genetic and environmental factors that may 
influence the onset of disease and certainly needs more investigation. 
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